Introduction {#s1}
============

Miscarriage is one of the most common yet under-studied adverse pregnancy outcomes. In the majority of cases the effects of a miscarriage on women\'s health are not serious and may be unreported. However in the most serious cases symptoms can include pain, bleeding and a risk of haemorrhage. Feelings of loss and grief are also common and the psychology and mental health of those affected can suffer ([@DMV041C64]).

For the purposes of this review 'miscarriage' is defined as the spontaneous loss of a pregnancy during the first 24 weeks of gestation (Fig. [1](#DMV041F1){ref-type="fig"}). For most women, a miscarriage is an individual event and will be followed by a successful pregnancy ('spontaneous miscarriage', termed 'miscarriage' from this point onwards). A small number (0.5--1%) of women wishing to have children may experience three or more successive miscarriages, a condition known as 'recurrent miscarriage' ([@DMV041C29]). 'Early miscarriage' is defined as pregnancy loss during the first trimester of pregnancy (less than 12 weeks of gestation) and occurs in up to one in five pregnancies. 'Late miscarriage' occurs during the second trimester (12--24 weeks of gestation) and is less common, occurring in 1--2% of pregnancies ([@DMV041C94]). Fetal death from the 25th week of gestation onwards is defined as stillbirth, an outcome taken into consideration in some of the studies included here, however it is not the main focus of this review. Figure 1Adverse pregnancy outcomes across the three trimesters of pregnancy.

Although miscarriage is considered the most common adverse pregnancy outcome, worldwide figures are not available. In 2012--2013 there were 729 674 live births recorded in England and Wales ([@DMV041C153]). Loss of one in five pregnancies suggests that this figure is accompanied by ∼200 000 miscarriages. Statistics from England and Wales for 2012/13 report that 39 800 miscarriages resulted in a hospital stay ([@DMV041C153]). In an Australian prospective cohort including 14 247 women aged 18--23 years, the rate of miscarriage varied from 11.3 to 86.5 per 100 live births amongst different groups; overall, miscarriage occurred in 25% of the women in the study when the women were 31--36 years old ([@DMV041C102]).

Aetiology of miscarriage {#s1a}
------------------------

The causes of miscarriage are often unknown. However, in ∼50% of early miscarriages the fetus exhibits chromosomal aberrations such as a structural alteration or abnormal chromosomal numbers ([@DMV041C61]; [@DMV041C182]). Several other factors have been associated with increased risk of miscarriage. The age of both parents has a significant role as the risk of an adverse pregnancy outcome is increased if the parents are 35 years old or older and it is 50% higher if the mother is 42 years of age ([@DMV041C73]; [@DMV041C152]; [@DMV041C52]; [@DMV041C177]; [@DMV041C128]). In addition, factors such as ethnic origin, psychological state of the mother, very low or very high pre-pregnancy BMI, feelings of stress, use of non-steroidal anti-inflammatory drugs, smoking and alcohol consumption have also been associated with significantly higher rates of miscarriage ([@DMV041C46]; [@DMV041C149]; [@DMV041C179]; [@DMV041C123]; [@DMV041C128]). Moreover, it has been reported that women whose first pregnancy resulted in miscarriage are at a higher risk of the second pregnancy resulting in miscarriage compared with women who had a live birth ([@DMV041C112]). Finally, a number of infections have been linked to miscarriage ([@DMV041C19]) and to other adverse outcomes, such as stillbirth ([@DMV041C85]) and preterm delivery ([@DMV041C79]). Specifically, 15% of early miscarriages and 66% of late miscarriages have been attributed to infections ([@DMV041C180]; [@DMV041C16]). In a recent study, 78% of 101 tissue samples from miscarriage were infected with bacteria (chorioamnionitis), whereas all the control samples from medically induced abortions were uninfected ([@DMV041C6]).

Methods {#s2}
=======

The aim of this review is to summarize present knowledge regarding the role of infection in miscarriage. In order to combine the most recent findings regarding infection and a potential association with miscarriage, we focused on studies published in the past 5 years. Our aim was to investigate current evidence regarding high-risk pathogens and scientific research trends. In PubMed, using the key words 'miscarriage' combined with 'infection' and 'infections', with 'human', 'English language' and '2009-present' filters, articles published in the past 5 years were identified. The search returned a total of 292 and 327 papers for 'miscarriage infection' and 'miscarriage infections' respectively (up to 02/06/2014). From these, single case reports and studies in animals were excluded. A total of 44 studies investigated the association of different pathogens with miscarriage and the findings are presented in this review. The studies were also scored by two individuals independently based on the Newcastle - Ottawa Quality Assessment Scale for case control studies. The score of random studies was further evaluated by two more individuals.

Results {#s3}
=======

Infections associated with miscarriage {#s3a}
--------------------------------------

An overview of all the studies analysed is presented in [Supplementary Table SI](http://humupd.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmv041/-/DC1), including pathogen(s) investigated, outcome of the study and an estimation on the strength of each study, as described in Methods. Some of the most common caveats addressed in this review were variation in sample size and detection techniques, whether multivariate analysis was implemented or not and variation in study design.

Bacterial infections {#s3b}
--------------------

### Bacterial vaginosis {#s3b1}

In healthy women, the normal genital tract flora consists for the most part of *Lactobacillus* species bacteria ([@DMV041C122]). Other potentially virulent organisms, such as *Gardnerella vaginalis,* group B streptococci*, Staphylococcus aureus, Ureaplasma urealyticum* (*U. urealyticum*) or *Mycoplasma hominis* (*M. hominis*) occasionally displace lactobacilli as the predominant organisms in the vagina, a condition known as bacterial vaginosis (BV) ([@DMV041C66]; [@DMV041C32]). BV is present in 24--25% of women of reproductive age ([@DMV041C164]; [@DMV041C202]) and causes a rise in the vaginal pH from the normal value of 3.8--4.2 up to 7.0. It is usually asymptomatic but may result in a vaginal discharge, which can be grey in colour with a characteristic 'ﬁshy' odour. BV is diagnosed using microscopic examination of vaginal swab samples for 'clue cells' and/or Nugent criteria and is commonly treated with antibiotics, such as metronidazole ([@DMV041C58]). Change of sexual partner, a recent pregnancy, use of an intrauterine contraceptive device and antibiotic treatment have been identified as plausible causes of BV ([@DMV041C94]; [@DMV041C178]). BV has been associated with premature delivery ([@DMV041C95]) and with miscarriage ([@DMV041C57]; [@DMV041C168]; [@DMV041C187]).

In a retrospective study from Albania, *U. urealyticum* and *M. hominis* were present in 54.3 and 30.4% of the patients (150 hospitalized women, presenting with infertility, who had had a miscarriage or medically induced abortion, [@DMV041C187]). The prevalence of both pathogens was significantly higher among women with a history of miscarriage (*U. urealyticum*: *P* = 0.04 and *M. hominis*: *P* = 0.02) and women who reported more than one miscarriage (*P* = 0.02 for both pathogens). This study however has some weaknesses, as it is not clear whether the comparisons made were with non-infected women with a miscarriage history or non-infected women with no miscarriage history and the method by which prevalence of microbes was tested is not specified.

Data on the prevalence of group B streptococci and pregnancy outcome in 405 Brazilian women with gestational age between 35 and 37 weeks was published in 2011 ([@DMV041C168]). Overall, 25.4% of women were positive for *Streptococcus agalactiae* and infection was associated, among other factors, with a history of miscarriage (odds ratio (OR) 1.875; 95% confidence interval (CI) 1.038--3.387).

Association of BV and particularly *M. hominis* and *U. urealyticum* was reported from a study from Turkey ([@DMV041C18]). In total 50 pregnant women with BV symptoms were tested for *M. hominis* and *U. urealyticum* and observed until end of pregnancy. The pregnancy outcomes of 50 asymptomatic pregnant women were used as controls. Miscarriage was reported in 12 symptomatic women, in 8 of which *M. hominis* and/or *U. urealyticum* infection was confirmed. However, the definition of miscarriage used in this study was 'less' than 36 weeks. Furthermore, comparative analysis between the two groups was not carried out.

*Ureaplasma urealyticum* was also detected in 25% of 101 gestational tissue samples (chorion, amnion, umbilical cord) from miscarriage cases that were otherwise normal. Second most common pathogens were *M. hominis* and group B streptococci at 11.1%, whereas all controls were not infected ([@DMV041C6]).

In a further study using a cohort of 759 Belgian pregnant women following microbiological evaluation of vaginal flora, 8.4% of participants in the cohort presented with BV and were not treated ([@DMV041C57]). BV was positively correlated with miscarriage, as 2% of positive women miscarried before 25 weeks gestation; with an OR of 6.6 (OR 6.6; 95% CI 2.1--20.9). An absence of lactobacilli was also associated with miscarriage (less than 25 weeks; OR 4.9; 95% CI 1.4--16.9, [@DMV041C57]).

These studies indicate an association of BV with miscarriage. As BV is treatable, screening programmes for pregnant women can be used to prevent adverse pregnancy outcome. Current guidelines from the USA advise against screening asymptomatic pregnant women ([@DMV041C193]). The same principle is applied in Canada ([@DMV041C209]) and the UK as of November 2014 ([@DMV041C195]). A recent Cochrane review, including 7847 women in 21 trials, found decreased risk of late miscarriage when antibiotic treatment was administered (relative risk (RR) 0.20; 95% CI 0.05--0.76; two trials, 1270 women, fixed-effect, *I*² = 0%). As the authors highlight, further studies are required to establish the effect of screening programmes to prevent adverse pregnancy outcomes ([@DMV041C25]).

### Brucellosis {#s3b2}

Bacteria of the genus *Brucella* can infect a variety of wild and domesticated mammals. Cattle and deer are susceptible to *Brucella abortus* (*B. abortus*) whereas *Brucella melitensis* affects goats and sheep, causing fever and abortion; a disease known as brucellosis ([@DMV041C11]; [@DMV041C142]). Humans can contract infection via consumption of unpasteurised dairy products ([@DMV041C45]). Infection is detected via bacterial isolation from blood samples or serology ([@DMV041C35]).

Kurdoglu and colleagues in Turkey ([@DMV041C121]), conducted a case--control study examining the miscarriage rate of 342 pregnant women with brucellosis compared with 33 936 uninfected women of similar socioeconomic status treated in the same hospital. The researchers concluded that 24.14% of infected pregnant women miscarried versus 7.59% of the controls. This result however could be influenced by statistical power, as the cases are ∼100 times smaller than the control group.

The seroprevalence of brucellosis among 445 miscarriage cases and 445 control pregnant Jordanian women with no history of miscarriage consecutively recruited, matched for age, socioeconomic status and area of residence, was not significantly different ([@DMV041C1]). In the paper the researchers state that a sample of 441 was adequate as the prevalence of brucellosis is 8% in high-risk patients in contact with livestock ([@DMV041C2]), though their reference for statistical power could not be reviewed. The overall prevalence was similar in both groups; 1% in controls and 1.8% in cases.

The evidence suggests brucellosis is still a risk factor for miscarriage in areas where the infection is endemic in farm animals. This is in accordance with older studies that have reported high miscarriage rates among women with brucellosis ([@DMV041C126]; [@DMV041C113]).

### Chlamydia trachomatis {#s3b3}

*Chlamydia trachomatis*, an obligate intracellular bacterium, is the most common sexually transmitted bacterial disease worldwide ([@DMV041C101]). The prevalence of the disease is high, estimated at 101 million new cases in 2005 worldwide ([@DMV041C211]). Though in women it is often asymptomatic, untreated *C. trachomatis* infection can result in mucopurulent cervicitis ([@DMV041C27]), acute urethral syndrome ([@DMV041C181]) and pelvic inflammatory disease (PID) ([@DMV041C157]). *Chlamydia trachomatis* infection is a known risk factor for ectopic pregnancy and preterm birth ([@DMV041C130]; [@DMV041C97]; [@DMV041C60]; [@DMV041C119]; [@DMV041C12]; [@DMV041C171]). Diagnosis is carried out by PCR on vaginal swab samples and treatment includes the administration of antibiotics, such as tetracyclines, azithromycin or erythromycin ([@DMV041C24]; [@DMV041C134]).

The most recent case--control study investigating a potential association of *C. trachomatis* and miscarriage was published in 2011 ([@DMV041C17]). Using an enzyme-linked immunosorbent assay (ELISA) to detect *C. trachomatis* antibodies in sera, as well as a standard vaginal swab for *C. trachomatis* detection by PCR, on 145 cases and 261 controls, a positive association with miscarriage was observed. Immunoglobulin (Ig)G antibodies against *C. trachomatis* were present in higher levels in the miscarriage group (15.2%) than in the controls (7.3%; *P* = 0.018). The same pattern was observed for IgA antibodies only after adjustment for age, origin, education and number of sexual partners. Furthermore, *C. trachomatis* was detected using PCR in the placentae from cases more often than those from controls (4.0 and 0.7% respectively, *P* = 0.026). Subsequently, an observational study from Finland on 4920 women with genital tract infections has suggested that late complications can occur in *C. trachomatis* infected pregnant women ([@DMV041C118]). However there was no control group in this study and neither were the terms 'early' or 'late' pregnancy defined, therefore limiting extrapolation of the findings.

In a study from Serbia, 21.3% of 54 miscarriage cases were shown to have persistent *C. trachomatis* infection as determined by levels of sera IgA against *C. trachomatis* major outer membrane protein ([@DMV041C10]). The authors suggest an association between persistent *C. trachomatis* infection and miscarriage, however these cases were compared only against patients with tubal infertility and not uninfected pregnant women.

*Chlamydia trachomatis* has been studied extensively and a lot of data are available for this infection from over three decades of research. Contradicting studies have been published, resulting in conflicting evidence regarding the role of *C. trachomatis* in miscarriage ([@DMV041C69]; [@DMV041C201]). Taking into account the most recent findings and the increase in screening programmes worldwide, such as the screening offered to all pregnant women in the USA ([@DMV041C37]), public awareness of the possible risk of *C. trachomatis* infection to a future pregnancy might be advisable.

### Mycoplasma genitalium {#s3b4}

*Mycoplasma genitalium* is a sexually transmitted bacterium, known to cause urethritis, cervicitis and PID, but infection can also be asymptomatic ([@DMV041C188]). It has been suggested that *M. genitalium* can enhance human immunodeficiency virus (HIV) infection and transmission ([@DMV041C148]); diagnosis is via PCR on urine samples ([@DMV041C36]) and treatments include azithromycin and doxycycline ([@DMV041C100]). The only published study of this infection, is a case--control study from the USA on 392 women with miscarriage before 22 weeks of gestation and 802 healthy pregnant controls, and used data from participants originally enrolled in another study. Overall, *M. genitalium* had a prevalence of 5.9% but no association with miscarriage was found ([@DMV041C172]).

### Q fever {#s3b5}

Q fever is a zoonotic infection, caused by the bacterium *Coxiella burnetii* ([@DMV041C132]). Infection is most commonly observed in humans who come into close proximity to livestock. *Coxiella burnetii* is usually transmitted via inhalation of infectious aerosols from animal fluids ([@DMV041C132]; [@DMV041C197]). Infection is asymptomatic in half of all cases in adults but can present as an unspecific illness combined with pneumonia or hepatitis. Q fever is confirmed via PCR on blood samples ([@DMV041C34]). Recommended treatment in symptomatic adults and children is doxycycline administration. In pregnant women, Q fever infection has been associated with adverse pregnancy outcomes, as in a recent report from the United States Centres for Disease Control and Prevention (CDC) ([@DMV041C9]). However, as the authors note, studies investigating serological evidence of infection and miscarriage have produced contradictory results. Screening of pregnant women is not currently recommended in the European Union ([@DMV041C145]).

Two Danish studies, one in 2012 and the second in 2013, concluded that *C. burnetii* is not linked to miscarriage ([@DMV041C150], [@DMV041C150]). Both used randomized sera samples from the Danish National Birth Cohort. The first study was powered to detect whether infection could be associated with miscarriage. The presence of infection was investigated in a case group of 218 women with miscarriage (loss of pregnancy prior to 22 weeks of gestation) compared with 482 healthy pregnancies. The second study focused on pregnancy outcomes of 397 women exposed to cattle and sheep (high risk of exposure to *C. burnetii* infection) versus 459 women that had no contact with animals. *Coxiella burnetii* prevalence was 5% in cases and 6% in controls of the first study, whereas in the second study 19.5% of all women were positive, however 87% of these women had contact with livestock. Nielsen and colleagues ([@DMV041C150]) reported one positive miscarriage case (0.46%) and 3 (0.67%) seropositive among controls whereas in the second study two miscarriages were positive ([@DMV041C151]). These results suggest that, despite presence of *C. burnetii* infection especially in pregnant women in proximity with cattle and sheep, this bacterium does not seem to be widely associated with adverse pregnancy outcome, although individual cases have been reported.

### Syphilis {#s3b6}

Syphilis is a bacterial infection that can be transmitted sexually or via contact with the blood of an infected person. It is caused by *Treponema pallidum*, diagnosed using PCR, and is treated with antibiotics ([@DMV041C44]). Stage one symptoms include a highly contagious sore that develops during stage two to a rash accompanied by sore throat. The third and final stage is tertiary syphilis, which is not contagious but is very harmful.

Casal and colleagues ([@DMV041C31]) assessed risk factors associated with syphilis and pregnancy outcomes in a Brazilian population. The cases consisted of women positive for syphilis, 169 with live births and 68 who had an adverse pregnancy outcome. This included miscarriage, stillbirth and neonatal death grouped together. The control group of women negative for syphilis included 219 women who had live births and 83 with adverse pregnancy outcome. Syphilis was significantly associated with history of miscarriage (OR 3.31; CI 2.20--4.99; *P* \< 0.0001) after testing using a multiple regression model. Most of the pregnancies resulting in live births were not completely asymptomatic when infection was present, resulting in outcomes such as prematurity, low birthweight and respiratory problems, among others. They also observed that maternal syphilis was associated with illegal drugs, alcohol, no counselling on syphilis, sexual activity initiation at 16 years of age or younger, two or more sexual partners during the preceding 1.5 years, life in a household with a low income and poorer sanitation; all factors that may also have a detrimental impact on reproductive outcome.

A study from China reported that, following a screening programme aiming to prevent mother-to-child syphilis transmission, the adverse pregnancy outcomes including miscarriage were reduced from 27.3% in 2003 to 8.2% in 2011 ([@DMV041C99]).

The effect of syphilis on pregnancy has been a subject of interest for almost 100 years; general consensus is that syphilis can have a devastating effect on fetuses resulting in miscarriage, stillbirth and congenital transmission ([@DMV041C189]; [@DMV041C156]). Syphilis screening programmes are in effect in the USA and EU ([@DMV041C37]; [@DMV041C103]).

Viral infections {#s3c}
----------------

### Herpes virus infections {#s3c1}

The Herpes family of DNA viruses includes a number of pathogenic viruses of humans (Human Herpes Viruses/HHV) that can remain latent in the host and can reactivate ([@DMV041C200]). Two members of this family, HSV-1 (HHV1) and HSV-2 (HHV-2) establish latency in neuronal cells and on reactivation can cause herpes genitalis or labialis ([@DMV041C129]). Cytomegalovirus (CMV) (HHV-5) is also a very common virus, acquired by most people during childhood ([@DMV041C41]). CMV infects mostly myeloid cells and is never eradicated from the body ([@DMV041C117]). Herpes viruses can be diagnosed using PCR in sera samples ([@DMV041C174]).

### HSV-1 and HSV-2 {#s3c2}

HSV1 and/or HSV2 DNA were detected in 43.5% of 95 frozen trophoblastic tissue samples from Greek women with spontaneous pregnancy loss compared with 16.7% of women undergoing elective abortion (*n* = 35, *P* = 0.03, Fisher\'s exact test) ([@DMV041C108]). Using *in situ* hybridization HSV DNA was detected in the trophoblast of 18 out of 25 HSV positive cases. The authors concluded that HSV seems to have a role in early miscarriage, although they did not distinguish between the two types of HSV.

These data are supported by a more recent study from Korea ([@DMV041C115]). The authors of this study tested sera of 500 pregnant women for HSV-2 and 85 (17%) were seropositive. Most of the women in both groups also tested positive for rubella, varicella zoster (HHV-3) and hepatitis B (HEPB), however the authors adjusted for this. Of HSV-2 seropositive women, 38.8% had a history of miscarriage compared with 29.6% of the control group (*P* \< 0.05).

A possible association of HSV1 and HSV2 with miscarriage cannot be ascertained from these reports and further studies are required.

### Human CMV/HHV-5 {#s3c3}

Hadar and colleagues studied a group of seropositive 59 women with peri-conceptional CMV infection, which occurred between 4 weeks prior to the last reported menstrual period and up to 3 weeks after the expected date of the period. Out of these women, four had miscarriages before undergoing amniocentesis to confirm intrauterine infection. The remaining patients either elected to terminate the pregnancy or gave birth to live infants. No conclusion could be drawn with regards to miscarriage association as no controls were included in this study ([@DMV041C90]).

Data from a Malaysian study ([@DMV041C169]) showed that anti-CMV IgG antibody was detected in 84% of healthy pregnant women as well as women with adverse pregnancy outcome, including 17 cases of miscarriage.

Despite the lack of recent studies supporting an association of CMV with miscarriage, *in vitro* studies have shown that CMV infection can result in placental dysfunctions (see below). However, further studies are required to elucidate the true role of CMV in adverse pregnancy outcomes.

### Human papillomavirus {#s3c4}

Human papillomaviruses (HPV) comprise a group of over 150 different types of small DNA viruses some of which cause common sexually transmitted infections ([@DMV041C49]). Sexually transmitted HPV infection has a prevalence rate of 11.7% in the general female population of reproductive age ([@DMV041C28]). According to CDC, sexually transmitted HPV prevalence nationwide in the USA among women 14--59 years old was 42.5% in 2003--2006, an estimation based on positive servicovaginal swab tests ([@DMV041C93]). Persistent infection with high-risk types of HPV (the most prevalent being HPV 16/18 worldwide) have been associated with cervical cancer, and others (HPV 6/11) with genital warts ([@DMV041C49]; [@DMV041C48]). The vast majority of infections are asymptomatic and clear naturally without causing long-term disease and a vaccine is now available for types 6, 11, 16 and 18 ([@DMV041C49]). HPV infection cannot be diagnosed by blood tests, however PCR on cervical cell samples is used to determine specific viral genotypes following a positive Papanicolaou (PAP)-test ([@DMV041C141]).

The results of recent studies into the effects of HPV infection upon miscarriage are contradictory ([@DMV041C159]; [@DMV041C176]; [@DMV041C205]). A study in China on the effect of HPV on the pregnancy outcome of IVF treated patients found no difference in miscarriage rates between women with abnormal cervical cytology who had a positive high risk HPV test (*n* = 56) and those who tested negative for high-risk HPV (*n* = 56, [@DMV041C205]). A second study from Poland tested for 33 HPV genotypes and also for specific HPV 16/18 DNA presence in placentae from miscarriages (*n* = 51) and from term deliveries from women who showed no signs of systemic infection (but were not tested, *n* = 78). They found HPV DNA in 17.7% of miscarriage cases and in 24.4% control placentae. A total of 11.8% of miscarriages and 12.8% of normal placentae were positive for HPV 16/18, but none of these differences reached statistical significance ([@DMV041C176]). Both of these studies suggest that HPV infection in women has no effect on pregnancy outcome, although no more than 150 women were examined in either study.

Conversely, results from a 2011 study significantly associated male partner HPV infection with miscarriage rate in 199 couples attending IVF clinics in Italy (66.7% in HPV infected couples versus 15% of controls with no HPV infection, *P* \< 0.01, [@DMV041C159]). The researchers also identified that all pregnancies in couples where both partners were infected resulted in miscarriage (*n* = 9).

These studies present contradictory data, however the first two examined infection in female partners whereas the second one investigated male partners. Interestingly, an older study ([@DMV041C96]) reported HPV DNA presence in 15/25 early miscarriage samples compared with 3/15 first trimester elective abortion samples. Further well-designed, adequately powered studies are required to fully elucidate the role of HPV as a potential risk factor for miscarriage, whilst considering the role of an infected male partner as there are indications of a potential role in early miscarriage ([@DMV041C80]).

### Parvovirus infection {#s3c5}

Parvoviruses belong to the Parvoviridae family and are very small single stranded DNA viruses that infect invertebrates and vertebrates ([@DMV041C47]). Of interest to studies of miscarriage are Adeno-associated virus (AAV), Parvovirus B19 (B19V) and Bocavirus (BC).

### AAV {#s3c6}

Antibodies against several serotypes of AAV show infection in various tissues, but it is asymptomatic ([@DMV041C77]). AAV needs the help of a helper virus, adenovirus, to replicate. Despite this, 80% of the human population is seropositive for AAV, as diagnosed by PCR ([@DMV041C86]).

No association of AAV infection with serotypes 2, 3 and 5 with recurrent miscarriage (defined as two or more) was found in couples with subfertility ([@DMV041C170]). A total of 146 semen samples as well as 134 endocervical samples from couples attending a fertility clinic were tested for the presence of AAV DNA and 14.9% of female and 19.9% of male samples were positive. No associations with other infectious pathogens, semen quality or subsequent fertility issues were indicated.

In another study ([@DMV041C158]), the presence of AAV was examined in 81 patients, divided into three groups: 13 medically induced abortions, 29 miscarriages and 39 'undetermined' (including 66 decidua and 52 ovarian biopsies from the same patients). AAV DNA was detected in 23/81 (28.4%) of cases for at least one of the decidual or ovular fragments. Furthermore, 22/68 (32.3%) of spontaneous and 7.7% (1/13) of elective abortions (classified according to patient information) tested positive. The authors grouped cases with confirmed type of abortion and observed 28.6% (12/42) and 2.4% (1/42) AAV positive 'for spontaneous and medically induced abortion, respectively (*P* \< 0.05)'. The classification of samples used as well as definition of the various groups compared in this study are unclear from the paper description, thus interpretation is challenging. The authors suggest a 'casual association' of AAV to miscarriage.

Despite the detection of AAV DNA in some miscarriage cases, there is inconclusive evidence for a role for this virus in miscarriage.

### Parvovirus B19 (B19V) {#s3c7}

Parvovirus B19 (B19V) is a small virus capable of causing different diseases in humans, such as 'Fifth disease' during childhood ([@DMV041C208]). It is estimated that ∼50% of young men and women have antibodies against B19V, determined via serology tests ([@DMV041C26]). The remaining 50% of women are at risk of developing infection during pregnancy, which can lead to non-immune hydrops fetalis, a well-established cause of fetal death ([@DMV041C173]).

A recent study from Northern Ireland examined 3921 women of reproductive age and 33.5% of them were at risk of infection as they had no antibodies against B19V ([@DMV041C199]). Though fetal loss was reported in infected women with confirmed presence of the virus in miscarried fetuses, no increased association with miscarriage was observed. However, the authors reported 'inadequate follow-up' of pregnancies potentially associated with B19V infection.

In an earlier study of 72 pregnant women with B19V, it was noted that the risk of vertical transmission is higher if infection occurs by gestational week 20. Six out of eight cases of fetal loss observed were 'attributed to B19V infection' without further elucidation. No conclusions regarding the association were reached by the researchers ([@DMV041C22]).

A higher percentage of IgM antibodies indicating recent infection was observed in women with adverse pregnancy outcomes (22.72%, *n* = 88) compared with 4.5% observed in 88 control healthy pregnant women ([@DMV041C23]). Interestingly, anti B19V IgG antibodies were higher in controls than cases (70.5 and 53.4% respectively, *P* = 0.046). An important limitation of this study is that the adverse pregnancy outcome included miscarriage, non-immune hydrops fetalis and intrauterine fetal death, thus the association of miscarriage alone with B19V is not clear.

In a study from Nigeria, B19V prevalence among pregnant women was estimated at 40.7%, as 111 out of 273 patients in the study had detectable levels of either IgG or IgM antibodies, however these were not associated with a history of miscarriage ([@DMV041C63]).

From the above, it is evident that a case--control study on women with miscarriage versus healthy pregnant controls, statistically powered to elucidate the role of B19V in miscarriage is required, as there are indications of high prevalence in pregnancy and fetal infection.

### Bocavirus (BC) {#s3c8}

The human BC is a newly discovered member of the parvovirus family detected in 93% of sera of children older than 3 years old ([@DMV041C110]). In a study on 535 fetal biopsies (120 miscarriages, 169 intrauterine fetal deaths and 246 induced abortions), even though only 10% of women were seronegative, none of the fetuses tested positive and the authors concluded that BC could not have a possible role in miscarriage ([@DMV041C167]).

### HIV {#s3c9}

HIV is a retrovirus, and is most commonly transmitted via unprotected sexual intercourse or sharing of equipment for intravenous drug use. There are two types of HIV, HIV-1 and HIV-2, with the first being the most common ([@DMV041C83]). The virus infects several cell types of the host immune system, such as CD4+ T lymphocytes ([@DMV041C138]; [@DMV041C62]), macrophages ([@DMV041C155]) and dendritic cells ([@DMV041C88]). Worldwide, the World Health Organization (WHO) estimates that 34 million people are living with HIV, diagnosed by HIV viral load blood tests (PCR) ([@DMV041C203]). Anti-retroviral treatment delays the onset of severe symptoms and protects the patient from opportunistic infections, which are the main cause of death among HIV-positive patients ([@DMV041C59]).

A 2013 study from Nigeria examined 2381 pregnancies in 1702 women positive for HIV compared with 2381 pregnant non-infected women from the same hospitals. Following preterm delivery, miscarriage was significantly associated with HIV positivity (OR: 1.37; CI: 1.1--2.3). This association was retained after adjustment for several confounding variables such as age, parity, history of miscarriage and others. The infected women in this study were all receiving anti-retroviral treatment, however different regimes were used during the years in which the study was conducted. Limitations of this study include the number of controls not being clearly stated and lack of testing for other sexually transmitted diseases ([@DMV041C68]).

In a study in Zambia 1229 HIV-positive pregnant women were followed up ([@DMV041C114], [@DMV041C115]). The ratio of miscarriages to live births was 3.1/100 and CD4 counts less than 350 cells/mm^2^ were significantly associated with miscarriage. The women were recruited during both first and second trimesters and none of the women who miscarried had received anti-retroviral treatment. The study did not compare the cases with uninfected pregnant women.

In a study of 382 Ugandan/Zimbabwean HIV-infected pregnant women undergoing multiple anti-retroviral therapies ([@DMV041C81]), miscarriage and medically induced abortions occurring prior to 22 weeks of gestation were assessed as one factor, not separate outcomes. Of note, fetal death after 22 weeks was classified as stillbirth. Therefore, no conclusions regarding miscarriage specifically can be drawn from this study. A study from India on 69 HIV-infected and 345 non-infected women demonstrated higher miscarriage/stillbirth risk amongst the infected group, however again there was no distinction between medically induced abortions and miscarriages ([@DMV041C50]). In a retrospective analysis from Germany, 42% of HIV-positive women attending an outpatient clinic for preconception counselling became pregnant and only one miscarried ([@DMV041C82]).

HIV status was associated with miscarriage in a study of 1,218 pregnant women from Uganda ([@DMV041C51]). However, they defined stillbirth as the delivery of a non-living fetus ≥28 weeks gestation; and miscarriage as the delivery of a non-viable fetus either at \<28 weeks gestation or weighing \<500 g. Furthermore, as stillbirth and miscarriage were grouped together as one outcome, no definite conclusions regarding miscarriage can be drawn from this study.

To summarize, evidence suggests that HIV infection negatively affects pregnancy; however, anti-retroviral treatment can reduce the risk of adverse outcomes ([@DMV041C210]; [@DMV041C75]). Furthermore, HIV has been associated with BV which could have a detrimental role on pregnancy outcome ([@DMV041C125]). The presence of multiple diseases could further compromise a pregnancy. As most of the studies suggest, consultation and monitoring of HIV-positive women who wish to become pregnant is desirable. Women during their first antenatal visit are offered HIV tests in the UK, USA and EU ([@DMV041C67]; [@DMV041C194]; [@DMV041C37]).

### Polyomavirus BK {#s3c10}

Polyomavirus BK infects up to 90% of the general population via an unknown transmission route and is usually asymptomatic with the exception of immunocompromised individuals ([@DMV041C98]). Antibodies against the virus can be detected using sera samples and PCR, urine cytology and viral immunostaining ([@DMV041C131]).

Recent studies have investigated a potential role of BK virus infection on adverse pregnancy outcomes. A study on patients with unexplained villitis (infection of the placental villi associated with adverse pregnancy outcomes) detected no BK in placenta from miscarriages ([@DMV041C30]). The authors state that 'For cases with diffuse villitis, the gestational age ranged from 31 to 41 weeks (average 37.2 weeks)'. It seems therefore more suitable to address these cases as stillbirths, not miscarriages. In another study from Italy, samples from five miscarried fetuses with chorioamnionitis and miscarriages due to chromosomal abnormalities (controls), BK was detected in fetal organs ([@DMV041C21]). Though this provides possible proof of vertical transmission of the virus, as it was detected in four out of five chromosomally abnormal controls and three out of five cases, the authors concluded that BK infection does not have a role in miscarriage. In accordance with the first study, the fetuses were between the 15th and the 28th week of gestation, so some of them were stillbirths according to our review\'s classification. Moreover, the fetuses were not matched for gestational age. In both studies, the numbers were small and no early miscarriages were tested. The question whether BK virus could be associated with miscarriage requires therefore further investigation.

### Dengue fever {#s3c11}

Dengue fever is a disease caused by four viruses of the single stranded RNA flaviviridae genus (DEN1-4), transmitted via mosquito bites usually in tropical and sub-tropical climates worldwide. WHO estimates 40--50 million new cases every year. Dengue is a flu-like illness with no vaccination and treatment currently available. Diagnosis is difficult as symptoms resemble other diseases, however usual approaches include DNA and antibody detection in serum samples using PCR and ELISA, respectively ([@DMV041C33]).

The role of dengue fever in miscarriage was examined in a prospective study from Malaysia on 115 women with miscarriage up to 22 weeks of gestation and 296 healthy pregnant controls. This study found significant association of recent dengue fever infection with miscarriage after adjusting for confounders such as maternal age, gestational age, parity and ethnicity (5.3% in cases versus 1.7% in controls, adjusted OR 4.2, 95% CI 1.2--14, *P* = 0.023, [@DMV041C185]).

In a case series report from Sri Lanka, two out of fifteen pregnant women experienced fetal death at 24 and 35 weeks of gestation, however the study provides no evidence of vertical transmission to the fetuses ([@DMV041C111]). In another case series report from French Guiana the authors reported two late miscarriages in 53 pregnant women with dengue fever. However, the infection could not be connected to the adverse pregnancy outcome ([@DMV041C15]).

A systematic review on 30 studies concluded that it is unclear whether dengue fever is associated with adverse pregnancy outcomes ([@DMV041C162]). Based on recent evidence however, we can conclude that dengue fever seems to be a risk factor for miscarriage; therefore it is advisable to raise awareness regarding protective measures in high-risk areas and for people travelling to those areas.

### HEPB and HEPC {#s3c12}

The HEPB virus is a member of the Hepadnavirus family of small DNA viruses and the HEPC virus is a member of the flaviviridae genus of single stranded RNA viruses. Both viruses cause liver inflammation and disease and are both found in body fluids. HEPB is often resolved within a couple of months, however HEPC can develop into a chronic disease. Both diseases are diagnosed using blood serological tests ([@DMV041C87]; [@DMV041C120]).

In a case--control study from China, 75 couples that received assisted reproduction treatment were followed up, divided into a group with one partner diagnosed with chronic HEPB infection and a control group with both parents seronegative for HEPB ([@DMV041C206]). The early miscarriage rate (gestational week range not specified) was 44% in the case group compared with 9.1% in the control group (*P* = 0.043, Fisher\'s exact test). Highest miscarriage rates (60%) were observed when mothers were seropositive and fathers seronegative (*P* = 0.03). Using PCR, HEPB DNA was detected in 6/62 'abandoned embryos' from the case group, whereas all embryos of the control group were negative. These results suggest a possible role of chronic HEPB infection in miscarriage.

Conversely, a cross-sectional study from Yemen examined the association of miscarriage with HEPB and HEPC infection in pregnant women, and found that 10.8% of women were positive for HEPB (95% CI: 8.0--14.0%) and 8.5% for HEPC (95% CI: 6.0--11.5%). No association of infection with miscarriage was apparent after multivariate analysis ([@DMV041C146]).

These studies raise questions regarding the role of persistent HEPB infection during pregnancy. At the moment, screening programmes of pregnant women for HEPB and HEPC during their first antenatal visit in the USA and UK aim to prevent adverse pregnancy outcome ([@DMV041C194]; [@DMV041C37]).

### Rubella {#s3c13}

Rubella is a mild childhood disease that, if acquired during the first 16 weeks of gestation, can result in miscarriage and serious fetal defects ([@DMV041C14]). A vaccine has been available for several years resulting in significant reduction in new cases according to the latest WHO progress report ([@DMV041C166]). Regardless of this progress, it is important to be aware that there remain a number of unvaccinated pregnant women in Europe and worldwide that do not have access to vaccination and who are still at risk of adverse pregnancy outcome due to rubella ([@DMV041C136]; [@DMV041C147]).

### Influenza virus {#s3c14}

A study of the 1918 Influenza pandemic concluded that it resulted in a decrease of live births due not only to high mortality but also to an increase of early miscarriages in pregnant women who were infected by the virus ([@DMV041C20]). In a case series report regarding the H1N1 Influenza A pandemic, six women were admitted to intensive care and had adverse pregnancy outcomes, however only one seriously ill patient had a spontaneous abortion as four cases occurred during the third trimester ([@DMV041C154]).

Protozoan infections {#s3d}
--------------------

### Malaria {#s3d1}

Malaria is caused by infection with protozoa of the genus *Plasmodium (P. falciparum, P. vivax, P. malariae, P. ovale*), is transmitted via mosquito bites and is endemic in more than 100 countries in Africa, Asia and South America ([@DMV041C203]). In 2012 there were an estimated 207 million cases of malaria resulting in an approximately 627 000 deaths (90% of all malaria deaths occur in sub-Saharan Africa) ([@DMV041C204]). Symptoms include fever, sweats, headache and diarrhoea and can be treated using different drugs depending on the symptoms and the specific pathogen causing the disease such as atovaquone plus proguanil or doxycycline ([@DMV041C109]). Malaria parasites are identified by microscopit examination of patients\' blood samples. In 2007, 54.7 million pregnancies occurred in areas with endemic *P. falciparum* malaria and a further 70.5 million in areas with exceptionally low malaria transmission or with *P. vivax* only ([@DMV041C54]). Plasmodium can bind chondroitin sulphate A expressed on trophoblast and this is what causes local parasitaemia in the placenta ([@DMV041C4]). Maternal disease is most severe in primigravida women, and it reduces with each pregnancy as immunity builds up to those parasites that target the placenta ([@DMV041C74]).

Women with asymptomatic and symptomatic malaria (single episode before 14 weeks of gestation) are at a higher risk of miscarriage (adjusted OR 2.70, 95% CI 2.04--3.59 and 3.99, 95% CI 3.10--5.13, respectively). This study included 3527 women with miscarriage and 14 087 women that gave birth to live babies in Thailand. The risk ratios were not different for both *P. falciparum* and *P. vivax* ([@DMV041C133]).

[@DMV041C51] also studied malaria during pregnancy in Uganda. In 1218 pregnant women no association of malaria with adverse pregnancy outcome was shown but an association with HIV status was demonstrated, as described above.

An association of malaria with adverse pregnancy outcomes, and more specifically miscarriage, is evident from the above studies. Prevention measures and screening of pregnant women at risk of malaria infection are advised.

### Toxoplasmosis {#s3d2}

Prevalence of Toxoplasmosis differs across the world, from 20--40% in the UK and USA ([@DMV041C72]) to ∼70% in tropical countries ([@DMV041C116]). In a recent study from London, 17.32% of 2610 samples tested were seropositive ([@DMV041C71]). Even though most patients are asymptomatic, immunocompromised individuals are susceptible to developing severe disease and women who become infected whilst pregnant can pass the infection vertically ([@DMV041C105]). The presence of *T. gondii* is confirmed by antibody detection.

[@DMV041C8] showed that 6.7% of 326 women with a history of miscarriage had been exposed to *T. gondii*. This study however did not include a control group with no history of miscarriage. Miscarriage or stillbirth occurred in 28 out of 190 pregnant cases with toxoplasmosis presenting in England and Wales between 2008 and 2012, however these are data from the surveillance programme currently in place and not part of a study ([@DMV041C92]). In a study on serum samples from 100 women who had miscarried, 86% of which were during the first trimester of pregnancy, 55% were seropositive for IgG against *T. gondii* ([@DMV041C196]), however, no comparison to uninfected pregnant women was made. A meta-analysis of several Mexican studies also indicates that infection rates are higher in women with miscarriage ([@DMV041C76]). Despite this, as the authors highlight, only three out of the 132 studies included in their systematic review, were focused on women who had a miscarriage.

The likelihood of association of *T. gondii* infection resulting in miscarriage is highlighted by the present review of recent studies. Taking into account the significant worldwide prevalence of this protozoan infection, screening of pregnant women is recommended if it is established that this infection presents a significant risk for adverse pregnancy outcome.

How do infections lead to miscarriage? {#s3e}
--------------------------------------

Pregnancy is a complex process involving multiple cell types and regulated by several sophisticated mechanisms, which are still not fully clarified despite years of research. To examine the negative impact of infections to pregnancy, we first need to understand how a normal, successful pregnancy is established.

### Maternal-fetal interface: morphology, implantation process and the role of the immune system {#s3e1}

The human endometrium is composed of several different cell types, including luminal and glandular epithelial cells, stroma with stromal fibroblastic cells, immune cells and blood vessels. During every menstrual cycle, in response to ovarian estrogen and progesterone via a process called 'decidualisation', the endometrial stromal compartment undergoes morphological and structural transformation to become receptive to implantation. Prior to implantation, the trophoblast differentiates into the growing blastocyst as it travels from the Fallopian tube to the uterus. The 'implantation window', during which the uterus is receptive to the embryo, is usually between 6 and 12 days after ovulation ([@DMV041C165]). The blastocyst attaches to the receptive endometrium utilizing adhesion proteins, called integrins, during the implantation window (Fig. [2](#DMV041F2){ref-type="fig"}A, [@DMV041C135]). Placenta formation begins as the trophoblast comes into contact with the epithelium and differentiates further into syncytiotrophoblast that invades the epithelial layer. Various other molecules, both from the maternal and fetal side, are involved in this process (reviewed in [@DMV041C55]; [@DMV041C192]; [@DMV041C3]; [@DMV041C40]). Syncytiotrophoblasts, supported by the decidualised stroma ([@DMV041C84]), penetrate the endometrium and surround the embryo, whilst it embeds itself in the decidual stroma. A second trophoblast layer, the cytotrophoblast, is an inner layer without contact with the maternal cells. During the trophoblast invasion, cavities called lacunae develop, which, as they get filled with maternal blood, bring the maternal circulation into contact with the placental villi, thus marking the onset of placental circulation that includes exchange of nutrients and waste between the embryo and mother. At days 10--12 of gestation, the embryo is completely embedded in the endometrium, the epithelium has grown over it and the implantation process is complete (Fig. [2](#DMV041F2){ref-type="fig"}B). The three placental zones are now distinguishable: the early chorionic plate near the embryo, the intervillous space with the villous trees and the primitive basal plate in contact with the maternal endometrium ([@DMV041C160], [@DMV041C161]). Simultaneously, endovascular trophoblast cells stemming from the basal plate invade the walls of the spiral arteries, replacing the maternal muscular and endothelial cells with trophoblast cells, transforming the arteries into large diameter and low resistance blood vessels ([@DMV041C127]). Figure 2Implantation of blastocyst in the maternal endometrium. (**A**) During the implantation window (Day 6--12 post conception), the blastocyst adheres to the endometrium, and the placenta formation commences as the syncytiotrophoblast develops and invades the endometrium. (**B**) On Days 10--12 the implantation is completed as the embryo is encapsulated within the maternal tissue and the endometrial spiral arteries have been transformed into low resistance blood vessels, thus marking the onset of the placental blood flow.

The role of the immune system in a successful pregnancy is crucial (Fig. [3](#DMV041F3){ref-type="fig"}A). Whilst the immune tolerance of the semi-allogeneic fetus is maintained, several components of the immune system fulfil their designated roles in preparation for implantation as well as during gestation ([@DMV041C65]; [@DMV041C39]). Natural killer (NK) cells, macrophages and dendritic cells have all been detected in the feto--maternal interface ([@DMV041C89]; [@DMV041C140]; [@DMV041C78]). Cytokines such as interleukin (IL-10), colony stimulating factor (CSF-1) and transforming growth factor-β among others have been linked with the implantation process and are expressed in uterine cells ([@DMV041C7]; [@DMV041C89]; [@DMV041C190]). Implantation induces an inflammatory response because of invasion and damage of maternal tissue, with many cells undergoing apoptosis ([@DMV041C104]; [@DMV041C107]). Conversely, inflammatory cytokines such as interferon-γ and tumour necrosis factor alpha (TNF-α) are not usually expressed in the placenta and have been associated with abortion in mouse models ([@DMV041C65]). Figure 3Healthy and infected feto--maternal interface. (**A**) During a healthy pregnancy, the interaction between maternal decidua, vasculature and immune cells (macrophages, uterine natural killer cells and dendritic cells) with fetal trophoblast and syncytial cells is the cornerstone of establishment and progression of pregnancy. Molecules such as interleukin (IL-10), colony stimulating factor (CSF-1) and transforming growth factor-β are essential for trophoblast invasion during the implantation process and are expressed by uterine cells. (**B**) Infections can disrupt the balance of feto--maternal interactions. *Plasmodium falciparum* can infect trophoblast cells entering via the maternal bloodstream. Cytomegalovirus and *Listeria monocytogenes* are examples of viral and bacterial infections known to interfere with trophoblast cells.

Abnormal implantation, placentation or blood vessel transformation are thought to result in miscarriage ([@DMV041C137]; [@DMV041C13]). An active infection could interfere with the pregnancy by affecting any of the above-mentioned processes as well as disrupt the immune balance, whether it resulted in placental and fetal infection or not.

### Examples of where we understand the mechanism of infection-induced miscarriage {#s3e2}

For most of the pathogens where an association has been demonstrated, the exact mechanism that leads from infection to miscarriage is unknown. Bacteria, protozoa and viruses utilize different mechanisms to infect their host and each one seems to induce a unique cascade of events in the feto--maternal interface, most of which remains to be determined. Our knowledge is derived mostly from animal studies and data on human pregnancies are scarce.

Multiple mechanisms can be utilized by pathogens to cross the placental barrier. Plasmodium, as mentioned previously, enters the host via the maternal circulation and can infect and multiply in the trophoblast (Fig. [3](#DMV041F3){ref-type="fig"}B), even though its natural target cells are red blood cells ([@DMV041C4]; [@DMV041C143]). However, this mechanism of crossing the placental barrier is specific to malaria. *Listeria monocytogenes* uses two bacterial surface proteins called internalin A and B to invade the placenta, after passing from the intestinal barrier to the maternal circulation (Fig. [3](#DMV041F3){ref-type="fig"}B, [@DMV041C198]; [@DMV041C124]; [@DMV041C56]). The presence of pathogenic organisms in the placenta induces a maternal immune response to infection that could result in miscarriage.

The susceptibility of placenta and fetus to several viruses has been investigated, as trophoblast cells have been identified as targets and viruses such as AAV and CMV have been detected in fetal tissue. CMV has been shown *in vitro* to replicate in trophoblast cells (Fig. [3](#DMV041F3){ref-type="fig"}B), in addition to epithelial, stromal cells and macrophages that are known target cells of the virus ([@DMV041C139]; [@DMV041C70]; [@DMV041C175]). In trophoblasts, CMV can induce an inflammatory response that increases apoptosis ([@DMV041C42]). CMV has also been shown to activate TNF-α, again leading to cell death ([@DMV041C38]). TNF-α is normally expressed in low levels by the placenta ([@DMV041C65]); in the mouse CBA × DBA/2 model TNF-α was shown to increase fetal resorption via activation of NK cells, macrophages, and Th1-type cytokines ([@DMV041C43]). Furthermore, decreased levels of implantation-associated matrix metalloproteinases 2 and 9 (MMP2 and MMP9) in the early pregnancy villi of women with CMV indicate compromised invasive capability, that could result in miscarriage ([@DMV041C186]). These results suggest that CMV infection could lead to placental dysfunction as well as suggest possible routes of fetal infection resulting in miscarriage.

Bacterial infections initiate different responses from the immune system compared with viruses but gram-negative and gram-positive bacteria are both capable of activating the innate immune system ([@DMV041C184]; [@DMV041C207]). Most of our knowledge regarding bacterial infections and pregnancy comes from studies in mouse models. Nitric oxide and prostaglandins produced in the presence of bacterial lipopolysaccharides (LPS) were shown to be associated with embryonic resorption, as inhibition of this pathway reversed the effect in mice ([@DMV041C5]). Poor uterine receptivity and implantation failure due to exposure to bacterial LPS was also reported in another study in mice ([@DMV041C53]).

Bacteria, viruses and protozoa utilize various mechanisms to infect fetal and maternal tissues (Fig. [3](#DMV041F3){ref-type="fig"}B), a few of which have been elucidated yet several remain unknown. These pathways are possibly implicated in miscarriage caused by infection. Further research is however required, as understanding the exact mechanisms behind infection-induced miscarriages could lead to effective treatment and thus prevention.

Conclusions {#s4}
===========

A plethora of bacterial, viral and protozoan infectious agents have been investigated to determine whether they are associated with an increased risk of miscarriage. The evidence presented in this review shows that infections such as BV, malaria, CMV, dengue fever, brucellosis and HIV may adversely affect pregnancy outcome. In contrast, there is no current evidence to suggest that *C. burnetii*, adeno-associated virus, Bocavirus, Hepatitis C and *M. genitalium* are associated with miscarriage. More importantly though, the lack of consensus regarding the effects of *C. trachomatis, T. gondii*, HPV, HSV1, HSV2, Polyomavirus BK, Hepatitis B and B19V infection reveals a gap in knowledge that future research should address, as these pathogens could potentially be harmful to early pregnancy development (Table [I](#DMV041TB1){ref-type="table"}). This issue is of particular importance for public health practitioners as it could alter current policies of prevention of infection, diagnosis and treatment in pregnant women. Table ISummary of pathogens and their association with miscarriage.BacteriaVirusesProtozoaAssociated with miscarriageBacterial vaginosis (including *Mycoplasma hominis and Ureaplasma urealyticum*)BrucellosisSyphilisCytomegalovirusDengue fever (*Flavivirus)*HIVRubellaMalaria (*Plasmodium*)Little or no evidence for association with miscarriageCoxiella burnetiiMycoplasma genitaliumAdeno-associated virusBocavirusHepatitis CNoneConflicting evidence for association with miscarriageChlamydia trachomatisHuman papillomavirusHerpes simplex virus 1 and 2Parvovirus B19Polyomavirus BKHepatitis BToxoplasma gondii[^1]

Even in diseases such as malaria and rubella, where a causative role is established, the underlying molecular cause of miscarriage is still unknown. The mechanism that has been proposed to explain how CMV infection could undermine a pregnancy could apply to other intracellular pathogens. *Chlamydia trachomatis* and *U. urealyticum* have been detected in placental cells, therefore they could cause a similar response ([@DMV041C106]; [@DMV041C17]). It is well established that pregnancy is a balance between tolerance and rejection, as the maternal immune system is re-programmed to tolerate the allogeneic (paternal) fetal antigens ([@DMV041C191]). An active infection could destabilize this balance resulting in rejection, especially if it leads to a serious illness of the mother. Evidently, further research is required to understand the causes of pregnancy failure.

In severe maternal infection, such as with influenza, HIV, dengue fever and malaria, the maternal response may result in miscarriage instead of a direct placental infection effect. However, pathogens such as *Plasmodium* parasites and Dengue fever\'s *Flavivirus* are known to be detected in fetal tissue and placenta, as are a plethora of other pathogens (Table [II](#DMV041TB2){ref-type="table"}). This is of particular importance, as proof of vertical transmission that could interfere with an ongoing pregnancy is more likely to result in miscarriage than a maternal infection. Examination of fetal tissues from infected mothers is essential to clarify whether vertical transmission is possible for pathogens as this has not yet been elucidated and it is evident from recent studies that an association is likely: for example, brucellosis, *Mycoplasma genitalium* and *Coxiella burnetii* infections. A very significant issue is fetal specimen contamination in cases with presence in the vagina of common viruses, such as HPV and HSV, as this does not equate to causation of miscarriage. Table IISummary of the sites of detection of pathogens in the studies in the review.MicrobeSite of detectionFetus/placentaVagina/cervixSerology/maternal blood/maternal urinePaternal sampleAdeno- associated virus[@DMV041C158][@DMV041C170]\
[@DMV041C158][@DMV041C170]Bacterial vaginosis (including *M. hominis and U. urealyticum)*[@DMV041C6][@DMV041C168]\
[@DMV041C18]\
[@DMV041C57]Bocavirus[@DMV041C167][@DMV041C167]Brucellosis[@DMV041C121]\
[@DMV041C1]*Chlamydia trachomatis*[@DMV041C17][@DMV041C17]\
[@DMV041C118]\
[@DMV041C10]*Coxiella burnetii*[@DMV041C150], [@DMV041C151])Cytomegalovirus[@DMV041C90]\
[@DMV041C169]Dengue fever (*Flavivirus*)[@DMV041C15][@DMV041C185]\
[@DMV041C111]\
[@DMV041C15]Herpes simplex virus 1 and 2[@DMV041C108][@DMV041C114], [@DMV041C115]Hepatitis B[@DMV041C206][@DMV041C206]\
[@DMV041C146][@DMV041C206]Hepatitis C[@DMV041C146]HIV[@DMV041C68]\
[@DMV041C114], [@DMV041C115]\
[@DMV041C81]\
[@DMV041C50]\
[@DMV041C51]Human papillomavirus[@DMV041C176][@DMV041C205][@DMV041C159]Malaria *(Plasmodium)*[@DMV041C51][@DMV041C133]\
[@DMV041C51]*Mycoplasma genitalium*[@DMV041C172]Parvovirus B19[@DMV041C23]\
[@DMV041C63]Polyomavirus BK[@DMV041C30]\
[@DMV041C21]Syphilis[@DMV041C31]\
[@DMV041C99]*Toxoplasma gondii*[@DMV041C8]\
[@DMV041C92]\
[@DMV041C196]

One interesting outcome of our review was that studies regarding infections and pregnancy outcome were conducted worldwide. Despite this, it seems that most of the studies were from countries in the developing world where the prevalence of specific diseases is higher.

A commonly observed limitation of the studies presented in this review was that few studies tested for the presence of other pathogens except for the one of interest. Several pathogens are often associated with one another, such as HIV with BV and malaria ([@DMV041C125]; [@DMV041C183]; [@DMV041C51]).

Furthermore, the definition of terms, such as miscarriage and stillbirth, may differ from the ones generally accepted in some studies, as mentioned previously. For example, loss of pregnancy up to 36 weeks was considered miscarriage ([@DMV041C18]), or in other cases less than 22 gestational weeks ([@DMV041C150]). Universal terminology guidelines are required to establish effective scientific communication.

The impact of immunization, if a vaccine is available such as in the case of HPV, could be detrimental in cases of infection-induced miscarriage. However, vaccine development for some of the pathogens of interest in this review is a complicated process and has been unsuccessful so far ([@DMV041C91]; [@DMV041C144]).

To our knowledge, there are no EU guidelines regarding screening for infectious diseases in pregnancy. Current screening guidelines in the UK include offering tests for HepB, HIV, rubella (testing for susceptibility) and syphilis to pregnant women ([@DMV041C163]). Systematic screening for infections such as BV or CMV is not currently recommended in the UK. Without accounting for cost, screening for pathogens highlighted as high risk for miscarriage in this review should be reconsidered as an option worldwide.

New policies including public education to raise awareness and screening programmes for appropriate pathogens associated with adverse pregnancy outcomes could result in a decrease in the number of miscarriages.
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[^1]: HIV, human immunodeficiency virus.
